MNG1043
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.446
- PROTEIN_SECRETION+0.403
- MITOTIC_SPINDLE+0.336
- DNA_REPAIR+0.329
- PI3K_AKT_MTOR_SIGNALING+0.295
- UV_RESPONSE_DN+0.286
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.250
- PEROXISOME+0.249
- ANDROGEN_RESPONSE+0.246
- MYC_TARGETS_V1+0.221
Top 10 suppressed
- ANGIOGENESIS-0.350
- TNFA_SIGNALING_VIA_NFKB-0.307
- HEDGEHOG_SIGNALING-0.277
- ALLOGRAFT_REJECTION-0.269
- APICAL_SURFACE-0.260
- COMPLEMENT-0.254
- KRAS_SIGNALING_UP-0.249
- INFLAMMATORY_RESPONSE-0.240
- PANCREAS_BETA_CELLS-0.236
- KRAS_SIGNALING_DN-0.234
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1042 | — | — | 0.833 |
| 2 | MNG1024 | — | — | 0.808 |
| 3 | MNG975 | — | — | 0.803 |
| 4 | MNG1224 | — | — | 0.796 |
| 5 | MNG687 | — | — | 0.788 |
| 6 | MNG1206 | — | — | 0.773 |
| 7 | MDT-AP-0211 | Med | Medulloblastoma | 0.759 |
| 8 | MNG1216 | — | — | 0.758 |
| 9 | MNG1038 | — | — | 0.757 |
| 10 | SJEPD030580_D1.RNA-Seq | EPN | EPN Tumor | 0.757 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.446 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.403 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.336 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.329 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.295 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.286 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.250 | Inavolisib | — uncovered |
| PEROXISOME | 0.249 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.246 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.221 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.220 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.185 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.183 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.159 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.138 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.111 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.087 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.085 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.079 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.076 | Inavolisib | — uncovered |